Oculis (NASDAQ:OCS – Get Free Report) and Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.
Profitability
This table compares Oculis and Bayer Aktiengesellschaft’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oculis | -8,613.92% | -39.24% | -33.45% |
| Bayer Aktiengesellschaft | -3.12% | 16.10% | 4.27% |
Volatility and Risk
Oculis has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Bayer Aktiengesellschaft has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and price targets for Oculis and Bayer Aktiengesellschaft, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oculis | 1 | 0 | 7 | 0 | 2.75 |
| Bayer Aktiengesellschaft | 0 | 1 | 5 | 2 | 3.12 |
Oculis presently has a consensus target price of $38.57, suggesting a potential upside of 446.34%. Given Oculis’ higher probable upside, research analysts clearly believe Oculis is more favorable than Bayer Aktiengesellschaft.
Institutional & Insider Ownership
22.3% of Oculis shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Oculis and Bayer Aktiengesellschaft”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oculis | $1.45 million | 282.30 | -$119.44 million | ($1.71) | -4.13 |
| Bayer Aktiengesellschaft | $51.55 billion | 1.16 | -$4.10 billion | ($0.42) | -36.12 |
Oculis has higher earnings, but lower revenue than Bayer Aktiengesellschaft. Bayer Aktiengesellschaft is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.
Summary
Bayer Aktiengesellschaft beats Oculis on 8 of the 14 factors compared between the two stocks.
About Oculis
Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft is a German life sciences company headquartered in Leverkusen. Founded in 1863, it develops products and services in pharmaceuticals, consumer health and agriculture. Its Pharmaceuticals business offers prescription medicines, including treatments in areas such as cardiovascular disease, oncology, women’s health and eye care. Consumer Health sells nonprescription medicines and self-care products, with brands including Claritin, Aleve and One A Day. Through its Crop Science business, Bayer provides seeds, crop protection products and agricultural solutions for farmers.
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
